Eli Lilly Raises Annual Revenue Forecast as Obesity, Diabetes Drug Demand Stays Strong

3-line summary

• Eli Lilly raised its annual revenue forecast as demand for its obesity and diabetes drugs remained strong, with revenue soaring 48% driven by its GLP-1 medicines, according to the report.

This summary is our own processing of the source article; see the source link below for full context.